Skip to content

Dicaris Children

Levamisole

Eliminate parasitic roundworm and hookworm infections from the gastrointestinal tract in children

Active ingredient
Levamisole
Route
Oral use
Form
Tablet; Oral solution
Strengths
50mg

Prescription and consultation requirements for Dicaris Children vary by destination and are determined by the fulfilment partner.

Dicaris Children details

Therapeutic class
Imidazothiazole derivatives
Pharmacological class
Antinematodal agent; Nicotinic acetylcholine receptor agonist
Contraindications
hypersensitivity to levamisole; pre-existing blood disorders
Minor side effects
nausea; vomiting; abdominal pain; diarrhoea; dizziness; headache
Dosage forms
Tablet; Oral solution
Administration route
Oral use
Supply category
Prescription-only medicine (POM)
Manufacturer
Janssen
Storage instructions
Store below 25°C in a cool, dry place, protected from light.
Drug interactions
phenytoin; ivermectin; albendazole; alcohol
Precautions and warnings

risk of agranulocytosis with prolonged or repeated use; caution in epilepsy; caution in liver disease; concurrent microfilaraemia may cause transient fever

Moderate side effects

agranulocytosis; leukopenia; vasculitis; encephalopathy; hypersensitivity reactions

Serious side effects

agranulocytosis, requires immediate medical attention; vasculitis, requires immediate medical attention; encephalopathy, requires immediate medical attention

Patient summary

Eliminate parasitic roundworm and hookworm infections from the gastrointestinal tract in children

Mechanism of action

Dicaris Children contains levamisole, an anthelmintic of the imidazothiazole class. It acts as an agonist at nicotinic acetylcholine receptors on the muscle cells of parasitic nematodes, causing sustained stimulation and spastic paralysis. The paralysed worms are expelled from the intestine by normal bowel movements, clearing the infection.

Age restrictions

Paediatric formulation. Dosing based on body weight. Not recommended in children aged under 12 months without medical supervision.

Pregnancy and breastfeeding

Contraindicated during pregnancy. Safety not established. Breast-feeding should be avoided during treatment.